BiotechTube

Esomeprazole + Cimetidine

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stress Ulcer Prophylaxis

Conditions

Stress Ulcer Prophylaxis

Trial Timeline

Jul 1, 2014 → Feb 1, 2016

NCT ID
NCT02157376

About Esomeprazole + Cimetidine

Esomeprazole + Cimetidine is a phase 3 stage product being developed by AstraZeneca for Stress Ulcer Prophylaxis. The current trial status is completed. This product is registered under clinical trial identifier NCT02157376. Target conditions include Stress Ulcer Prophylaxis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02157376Phase 3Completed

Competing Products

20 competing products in Stress Ulcer Prophylaxis

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
52
agenT-797MiNK TherapeuticsPhase 1
25
Thermal stress and performance without a pre-cooling protocolPetros PharmaceuticalsPre-clinical
15
solifenacinAstellas PharmaApproved
85
SivelestatEli LillyPhase 1/2
41
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
Duloxetine hydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
duloxetine + PlaceboEli LillyPhase 2
52
Exenatide + InsulinEli LillyPhase 2/3
65
DuloxetineEli LillyPhase 3
77
duloxetine HClEli LillyApproved
85
Orforglipron + PlaceboEli LillyPhase 3
77
Duloxetine hydrochloride + placeboEli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85